The short version of Visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
== P == Pacinian corpuscle A type of rapidly adapting mechanoreceptor located deep in the skin, responsible for detecting vibration and pressure. Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage. In neuroscience, pain is studied through nociception, pain pathways, and perception. Paralysis The loss of voluntary muscle function, often caused by damage to the brain, spinal cord, or peripheral nerves. Paraneoplastic syndrome A rare disorder triggered by an immune response to cancer that affects the nervous system. Can lead to sensory, motor, or cognitive symptoms. Parietal lobe A region of the cerebral cortex located near the top and back of the brain, involved in processing somatosensory information, spatial orientation, and body awareness. Parkinson’s disease A neurodegenerative disorder characterized by tremors, rigidity, bradykinesia, and postural instability. Caused by loss of dopaminergic neurons in the substantia nigra. Parvocellular pathway A visual processing stream originating in small ganglion cells of the retina, responsible for high-acuity and color vision. Projects to the lateral geniculate nucleus. Periaqueductal gray (PAG) A midbrain region involved in pain modulation, defensive behavior, and autonomic regulation. Contains opioid receptors and descending pain control pathways. Peripheral nervous system (PNS) All nerves and ganglia outside the brain and spinal cord. It includes sensory and motor neurons as well as autonomic nerves. Periventricular Located near or surrounding the brain’s ventricular system.
They are Silesia (Upper and Lower), Pomerania, West Prussia-Posen, and East Prussia respectively. Schaumburg-Lippe is now part of Lower Saxony. Württemberg is now part of Baden-Württemberg. Possible boundary changes between states continue to be debated in Germany, in contrast to how there are "significant differences among the American states and regional governments in other federations without serious calls for territorial changes" in those other countries. Arthur B. Gunlicks summarizes the main arguments for boundary reform in Germany: "the German system of dual federalism requires strong Länder that have the administrative and fiscal capacity to implement legislation and pay for it from own source revenues. Too many Länder also make coordination among them and with the federation more complicated." But several proposals have failed so far; territorial reform remains a controversial topic in German politics and public perception. A state capital is called a Landeshauptstadt.
The agriculture sector employs 43.5% of the labour force and is a major source of foreign exchange. Pakistan produced 28.98 million metric tons of wheat in 2025/2026 (3% of global output), ranking 7th globally. Pakistan ranks fourth in cotton production, fifth in sugar production, and is the fourth-largest milk producer globally. Though land and water resources haven't increased proportionately, productivity gains, especially from the Green Revolution in the late 1960s and 1970s, significantly boosted wheat and rice yields. Private tube wells and High Yielding Varieties (HYVs) further augmented crop yields. Meat industry accounts for 1.4 percent of overall GDP.
=== Dependence === Flunitrazepam, as with other benzodiazepines, can lead to drug dependence. Discontinuation may result in benzodiazepine withdrawal syndrome, characterised by seizures, psychosis, insomnia, and anxiety. Rebound insomnia, worse than baseline insomnia, typically occurs after discontinuation of flunitrazepam even from short-term single nightly dose therapy.
=== Reagents === The diketopiperazine obtains from glycylserine is a reagent for the preparation of C-alkylated derivatives of glycine. This approach is useful for the production of unnatural amino acids with stereochemical control. The diketopiperazine skeleton protects both the N and O termini of the glycine. For this application, the diketopiperazine is O-alkylated with concomitant N-deprotonation to give what is called the Schöllkopf reagent.
Sources: en.wikipedia.org
=== MMPs in wound healing === During wound healing, matrix metalloproteinases serve as a cleanup team, breaking down old tissues to make room for new ones. MMP-8 from neutrophils jumps in early to clear debris and accelerate skin healing overall, while MMP-1 from collagenases enhances keratinocyte movement across collagen fibers, helping to begin the repair after injury. MMP-13 then takes over to reduce the size of the wound and initiate re-epithelialization. Faster closure is achieved by drawing the wound edges together. Meanwhile, by activating MMP-9 and directing keratinocytes to migrate into the gap, the gelatinases MMP-2 speed up the healing process, while MMP-9 itself promotes cell migration everywhere within the wound. Based on that, the stromelysins and other MMPs fine-tune the final stages. MMP-3 activates MMP-9 further and helps in the contraction of the wound, preventing scarring or tissue deformation, while MMP-10 secreted by keratinocytes at the wound edges to support the remodeling. MMP-7 ‘s main role is re-epithelialization, going through barriers like elastin and laminin allowing new skin cells to spread out, and MMP-12 manages the angiogenesis by making angiostatin, which controls new blood vessel growth preventing their overgrowth. These MMPs work together to balance the breakdown and rebuild, transforming the damaged tissue into healthy tissue.
Buspirone acts primarily on the serotonin 5-HT1A receptor. It behaves as a full agonist at presynaptic 5-HT1A autoreceptors in the dorsal raphe, reducing the firing of serotonin-producing neurons, and as a partial agonist at postsynaptic 5-HT1A receptors in forebrain regions. This difference in activity between presynaptic and postsynaptic sites is thought to result from variations in receptor density and coupling efficiency. Buspirone also has lower affinity for other serotonin receptors, including 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7, where it is thought to act primarily as an antagonist. In addition, buspirone has weak antagonistic activity at dopamine D2, D3, and D4 receptors, with preferential blockade of presynaptic D2 autoreceptors at low doses and postsynaptic D2 receptors only at higher doses. A major metabolite of buspirone, 1-(2-pyrimidinyl)piperazine (1-PP), circulates at higher levels than buspirone itself and is a potent α2-adrenergic receptor antagonist, which may contribute to some of buspirone's noradrenergic and dopaminergic effects. Buspirone has very weak affinity for α1-adrenergic receptors, and does not interact with the GABAA receptor. Buspirone has been found to produce antiaggressive effects in rodents. It can strongly increase oxytocin levels in rodents, maximally by up to 9-fold. Conversely, the drug did not affect oxytocin levels in humans, though it enhanced hypoglycemia-induced oxytocin elevation.
== Method of preparation == Most antivenoms are prepared by freeze drying (also called cryodesiccation or lyophilization). The process involves freezing the antisera, followed by application of high vacuum. This causes frozen water to sublimate. Sera is reduced to powder with no water content. In such an environment, microorganisms and enzymes cannot degrade the antivenom, and it can be stored for up to 5 years [at normal temperatures]. Liquid antivenoms may also be stored for 5 years, but they must be stored at low temperatures (below 8 °C/46 °F).
2° being the center (Bolivia) weakened by the forces of both (Argentina and Peru)". The first indications of this policy for the domain of the South Pacific occurred in the Conquest of Chiloé. After the first Chilean attempt to annex the archipelago failed, Simón Bolívar (Peru's dictator at the time), eager to curry favor with the Peruvian elite, began to consider sending an expedition to bring it under the sovereignty of Lima, based on the uti possidetis iuris (because Chiloé was under the direct administration of the Viceroyalty of Peru, and then, to this republic corresponded the territory), before Spain negotiated and ceded the island potentially to the United Kingdom or France, powers that were known to be interested in that territory, or the Chilotas attempted an expedition to some region of the South Pacific. For the Chilean government, having Bolivarian troops to the south and north (in 1825, after the occupation of Upper Peru, the forces of Bolívar went on to seize all the territory north of the Loa) was considered a threat to their sovereignty. For the same reason, Bolívar's offer to form a joint expedition that would include 2,000 Colombian soldiers was rejected. Finally, the ruler of Colombia and Peru would demand that the Freire government end the threat that royalist Chiloé posed to South America or annex it to Peru (Bolivar was willing to renounce Peruvian claims to the territory to avoid strengthening Peru economically).
Sources: en.wikipedia.org
In May 2015, the company announced the closure of its U.S. headquarters in Dublin, Ohio; in March 2015, it had 127 employees. In August 2016, Tim Hortons again changed presidents. In September 2016, Tim Hortons announced it would be expanding into the United Kingdom, with an unannounced number of locations to be built. Revenue in 2015 for Restaurant Brands International was US$4.0522 billion with a rise to $4.15 billion in 2016. Tim Hortons had 683 U.S. locations by the end of 2016, and total annual revenue of US$3.00 billion. In April 2018, Tim Hortons announced that they would be moving their head office along with its 400 employees to the Exchange Tower in downtown Toronto. In May 2018, the Reputation Institute reported that Tim Hortons had fallen from 13th to 67th in its study of Canada's most reputable companies, as "one of the largest moves down of all 250 companies it analyzed this year'" and that the brand was "still considered to have a 'strong reputation.'" In October 2018, Tim Hortons began to install self-serve kiosks at some locations in Ontario. In February 2019, Tim Hortons began to spread the installation of the self-serve kiosks across Canada.
==== Exotic forms ==== Water and other volatiles probably comprise much of the internal structures of Uranus and Neptune and the water in the deeper layers may be in the form of ionic water in which the molecules break down into a soup of hydrogen and oxygen ions, and deeper still as superionic water in which the oxygen crystallizes, but the hydrogen ions float about freely within the oxygen lattice.
=== Ancient === 350 BCE — The Greek philosopher Aristotle, arguably the first philosopher to make a serious attempt to scientifically explain aging, proposes his thesis on aging. He suggests that aging is a process by which human and animal bodies, which are naturally hot and wet, gradually become dry and cold, and theorizes that more moisture delays aging. 259–210 BCE — years of life of the Chinese emperor Qin Shi Huang, who united China under his rule. All his life he persistently searched for an elixir of youth and died trying, presumably taking "pills of immortality", containing mercury. 156–87 BCE — years of life of the Chinese emperor Wu of Han, who persistently tried to find a way to achieve immortality, mainly by means of magic. He used services of various magicians. But Wu of Han was not a naive person – he thoroughly rechecked their abilities and if he identified the person as a quack, he executed him. 63 BC–14 CE — years of life of Caesar Augustus, the first Roman emperor, who is considered one of the most effective leaders of the Ancient Rome. For him an eternal youth was an obsession. In particular, contrary to the Roman tradition to create statues as realistic as possible, he always ordered to portray himself young. There are many of his "youthful" statues but researchers still do not know how he looked in old age. 3rd–17th century — the period of alchemy. There are several directions in alchemy, and it was distributed over a huge territory.
GC Vitamin D binding protein, also referred to as Vitamin D binding protein (DBP), is a protein that is encoded by the GC gene in Homo sapiens (modern humans). DBP is genetically the oldest member of the albuminoid family and appeared early in the evolution of vertebrates.
to close the "true" loop. While the slow-responding dynamics in the physiology of glucose regulation is not beyond the mathematics of PID controllers, 50 years of patient-perspective "advancement" says it is beyond the corporate, congressional, and lobbying leaders. Also, the accuracy of existing continuous glucose monitoring systems poses a problem for an artificial pancreas.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.